Evidence map›Paper›PMID 40860652›Full record

ArticlePeerJ2025

Kinetics of anti-SARS-CoV-2 antibodies and hematological parameters in hospitalized pre-vaccination COVID-19 patients in Peru.

Salyoc Tapia-Rojas, Alexis Germán Murillo Carrasco, Maria J Pons, Manuel Ugarte-Gil, Ana Mayanga-Herrera

Abstract read
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Salyoc Tapia-RojasCancer and Stem Cells Research Group, Universidad Cientifica del Sur, Lima, Peru.
Alexis Germán Murillo CarrascoCentro de Investigação Translacional em Oncologia (LIM24), Departamento de Radiologia, Universidade de São Paulo, Sao Paulo, Brazil.
Maria J PonsGrupo de Enfermedades Infecciosas Re-Emergentes, Universidad Cientifica del Sur, Lima, Peru.
Manuel Ugarte-GilGrupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Cientifica del Sur, Lima, Peru.
Ana Mayanga-HerreraCancer and Stem Cells Research Group, Universidad Cientifica del Sur, Lima, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic exposed vulnerabilities in health systems and revealed variations in immune responses across populations worldwide. This study examined the kinetics of IgG and IgM antibodies against S1 and receptor-binding domain (RBD) proteins in hospitalized Peruvian patients prior to vaccination. Method: A total of 157 serological samples were collected from 44 hospitalized COVID-19 patients during Peru's first wave (August-October 2020) and stored at -80 °C. Anti-SARS-CoV-2 IgG and IgM antibodies were quantified using an in-house ELISA with recombinant Spike S1 and RBD proteins. Statistical analyses-including linear regression, Kaplan-Meier curves, and receiver operating characteristic (ROC) curves-were conducted to evaluate antibody kinetics, clinical correlations, and predictive accuracy. Results: IgG levels stabilized between days 10 and 15 of hospitalization, while IgM levels declined after day 10, with greater variability observed in severe acute respiratory distress syndrome (ARDS) cases. A significant positive correlation was found between IgG levels and lymphocyte counts (

Indexed as

Antibodies, ViralCOVID-19Immunoglobulin GImmunoglobulin MSARS-CoV-2AdultAgedFemaleHospitalizationHumansMaleMiddle AgedPeruSpike Glycoprotein, CoronavirusAntibodies, ViralImmunoglobulin GImmunoglobulin MSpike Glycoprotein, CoronavirusAntibodiesCOVID-19HospitalizationImmunityKineticsPeru

Identifiers

PMID40860652
PMCPMC12377358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.